Bristol Myers Squibb
OPDUALAG
Manufacturer:
Bristol Myers Squibb
Name:
OPDUALAG
HCPCS Code Descriptor:
Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
Category:
J Code
HCPCS:
J9298
NDC(s):
00003-7125-11
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
OPDUALAG is an Oncology drug manufactured by Bristol Myers Squibb and administered via the Intravenous route of administration. The J Code: J9298 is aligned to the drug OPDUALAG.
Opdualag belongs to the group of drugs known as antineoplastic combinations and is used to treat certain types of cancer. This drug is a combination two different medications known as nivolumab and relatlimab. Opdualag is administered to the patient via intravenous infusion over the course of 30 minutes. Opdualag is a branded drug manufactured by the Bristol-Myers Squibb Company. Patient assistance programs for Opdualag can be found through Bristol-Myers Squibb’s Access Support.
Access Pricing and More By Registering
HCPCS Added Date:
10/1/22
HCPCS Effective Date:
10/1/22
HCPCS Short Description:
Inj nivol relatlimab 3mg/1mg
Billing and Coding Guide:
https://www.bmsaccesssupport.bmscustomerconnect.com/servlet/servlet.FileDownload?file=00P4z00001ZRYQaEAP
Patient Assistance:
https://www.bmsaccesssupport.bmscustomerconnect.com/patient
